MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2

Duan, Shufeng; Dong, Xiushuai; Hai, Jing; Jiang, Jinghong; Wang, Wenxiang; Yang, Jing; Zhang, Wei; Chen, Caixia

doi:10.1016/j.biopha.2018.08.044

Cited by 37 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We predicted that there were 28 miRNAs bound to circ-MAN1A2 (based on Miranda and regRNA2.0 databases), among which hsa-miR-135a-3p had the smallest minimum free energy (Table S2), suggesting that circMAN1A2 was most likely combined with hsa-miR-135a-3p. miR-135a-3p is downregulated and serves as a tumor suppressor in ovarian cancer, 75 consistent with our hypothesis. We also predicted binding partners for hsa-miR-135a-3p using TargetScan and miRwalk; the top 6 scores were for SLC4A8, IKZF4, SMAGP, SP1, ERBB3, and CBX5 (Table S3).…”

Section: Discussionsupporting

confidence: 91%

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

View full text Add to dashboard Cite

Novel diagnostic and prognostic biomarkers of cancers are needed to improve precision medicine. Circular RNAs act as important regulators in cancers at the transcriptional and posttranscriptional levels. The circular RNA circMAN1A2 is highly expressed in nasopharyngeal carcinoma according to our previous RNA sequencing data; however, the expression and functions of circMAN1A2 in cancers are still obscure. Therefore, in this study, we evaluated the expression of circMAN1A2 in the sera of patients with nasopharyngeal carcinoma and other malignant tumors and analyzed its correlations with clinical features and diagnostic values. The expression levels of circMAN1A2 were detected by quantitative real‐time PCR, and the correlations of clinical features with circMAN1A2 expression were analyzed by χ2 tests. Receiver operating characteristic curves were used to evaluate the clinical applications of circMAN1A2. The results showed that circMAN1A2 was upregulated in nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer, with areas under the curves of 0.911, 0.779, 0.734, 0.694, and 0.645, respectively, indicating the good diagnostic value of circMAN1A2. Overall, our findings suggested that circMAN1A2 could be a serum biomarker for malignant tumors, providing important insights into diagnostic approaches for malignant tumors. Further studies are needed to elucidate the mechanisms of circMAN1A2 in the pathogenesis of cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…miRNA dysregulation is closely associated with a variety of cancer types, and previous studies have revealed that miRNAs may be associated with tumor progression and prognosis (19)(20)(21). Comprehending the molecular mechanism underlying the influence of miRNAs in the progression of cancer may help identify novel treatment strategies.…”

Section: Discussionmentioning

confidence: 99%

miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway

Zhang

Geng

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

There is increasing evidence demonstrating that disorders affecting microRNAs (miRs) influence tumorigenesis and progression, which results in a poor prognosis in patients with breast cancer (BC). In the present study, the precise molecular mechanism underlying the role of miR-320 in the progression of BC was investigated. Reverse transcription-quantitative PCR was conducted to determine mRNA expression, and western blot analysis was used to test protein levels. An MTT assay was conducted to detect cell viability and Transwell assays were used to analyze cell migration and invasion abilities. Furthermore, E74-like factor 3 (ELF3) protein density was tested via immunohistochemistry. Tumor volume was detected by xenograft tumor formation assay. The current results indicated that miR-320 expression was downregulated in BC tissues and cells, and was associated with a poor prognosis of patients with BC. Overexpression of miR-320 inhibited cell proliferation, migration and invasion via inhibition of the epithelial-mesenchymal transition and the PI3K/AKT signaling pathway in BC cells. Furthermore, it was revealed that the tumor size and weight were smaller in nude mice that had been transfected to overexpress miR-320. The luciferase reporter assay demonstrated the direct binding of miR-320 to the 3' untranslated region of ELF3 mRNA, which may further downregulate ELF3. Overall, the present results provided evidence that miR-320 may be a tumor suppressor in BC, and that the miR-320/ELF3 axis regulated tumor progression via the PI3K/AKT signaling pathway, which may represent a novel treatment strategy for BC.

show abstract

“…A similar inhibitory effect of miR-135a was revealed in pancreatic cancer by its targeting of Bmi-1 28 and in gallbladder cancer by its targeting of very low density lipoprotein receptor (VLDLR); the p38 MAPK pathway is the downstream signaling pathway of miR-135a-VLDLR 36 . MiR-135a suppressed cell proliferation and tumor growth in an ovarian cancer mouse xenograft model 27 , and this effect may be attributed to the regulation of C-C chemokine receptor type 2 (CCR2) by miR-135a 61 . The role of miR-135a in urological cancers has been intensively investigated.…”

Section: Biological Function Of Mir-135a In Cancer and The Relevant Smentioning

confidence: 99%

MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy

Cao¹,

Qiu²,

Ye³

et al. 2020

Cancer Biol. Med.

View full text Add to dashboard Cite

MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2

Cited by 37 publications

References 37 publications

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway

MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy

Contact Info

Product

Resources

About